Therapeutics and Clinical Risk Management (Nov 2019)
Hepatorenal Syndrome Type 1: Current Challenges And Future Prospects
Abstract
Antonio Facciorusso Gastroenterology Unit, University of Foggia, Foggia, ItalyCorrespondence: Antonio FacciorussoGastroenterology Unit, Department of Medical Sciences, University of Foggia, AOU Ospedali Riuniti, Viale Pinto, 1, Foggia 71100, ItalyTel +39 0881732110Fax +39 0881733545Email [email protected]: Renal dysfunction represents a dreadful complication of advanced liver cirrhosis. In addition to the traditional types of acute kidney injury (AKI) that can occur in the general population, cirrhotics might experience a different kind of renal dysfunction, called hepatorenal syndrome (HRS). The exact definition of HRS is a functional renal dysfunction caused by overactivity of the endogenous vasoactive systems (in particular intrarenal circulation) which lead to reduced renal perfusion. Type I HRS (HRS-1) is characterized by an abrupt deterioration in renal function (in less than 2 weeks), defined by a doubling of baseline sCr to >2.5 mg/dL or a 50% reduction in the initial 24 hrs creatinine clearance to Keywords: kidney, liver cirrhosis, terlipressin, mortality
